Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

April 9, 2021 Auto Bot Bio-Thera, Biogen, Biosimilar, Biosimilars, License, Moderate, rheumatoid arthritis, Severe, Signs, Treat 0

Shots:

  • Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21
  • Biogen to get exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries excluding China (includes Hong Kong, Macau, and Taiwan)
  • Biogen will expand its global biosimilars footprint with the potential approval of BAT1806 is a P-III clinical stage IL-6 receptor mAb that is a proposed biosimilar referencing Actemra (tocilizumab)

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Seeking Alpha

The post Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis first appeared on PharmaShots.